glp 1 drugs for alcohol use disorder GLP-1 linked to lower addiction rates in large study of veterans | Science GLP-1 plus therapy can reduce

Higher-risk patients include those in the dose-escalation phase, those with nausea, vomiting, bloating, abdominal pain, early satiety, or reflux symptoms, those on higher doses with GI side effects, and those with known gastroparesis or other conditions that slow gastric emptying

December 28, 2023

Increased postprandial glucagon-like peptide-1 (GLP-1) production after endoscopic gastrointestinal bypass using the Cousin lumen-apposing stent in a porcine model

Survodutide is a dual co-agonist combining properties of GLP-1 and glucagon receptor agonism in a single peptide molecule that has also been evaluated in a phase 2 study for weight loss

Physicians must conduct thorough screenings that account for contraindications including a history of pancreatitis, thyroid cancer, and eating disorders

Yu, H.-Y